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A CROSS SECTIONAL STUDY ON THE STATUS OF 
INFLAMMATORY MARKERS IN POLYCYSTIC OVARY 
SYNDROME (PCOS) PATIENTS IN INDIAN 
POPULATION 
ABSTRACT: 
AIMS AND OBJECTIVES: To assess the status of inflammation in 
patients with Polycystic Ovary Syndrome (PCOS) and to assess the 
influence of drugs prescribed for PCOS on inflammation. 
MATERIALS AND METHODS: Patients were divided into three 
groups as healthy volunteers, newly diagnosed PCOS patients, already on 
treatment patients for PCOS. hs-CRP, IL-6 and IL-18 were assessed. 
RESULTS: There was an increase in the hs-CRP, IL-6 and IL-18 
compared to healthy volunteers in both newly diagnosed and already 
diagnosed groups. But there was no statistical significance 
(hs-CRP=0.975, IL-6=0.746, IL-18 = 0.148) between them. The mean 
values has decreased in the already on treatment group as duration of 
treatment increases. There was no statistical significance between them. 
CONCLUSIONS: There was an inversely proportional relationship 
between the mean values of inflammatory markers and duration of 
treatment. 
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INTRODUCTION: 
In prehistoric times [pre-1700] the average life expectancy was twenty 
years. This was because of increased mortality during childhood. If one 
survives more than five years then it is likely that he will reach 
adulthood. During 1500-1600 it was 35-40 years.  This wide variation in 
mortality was due to war, famines and epidemics
1
. All our ancestors 
were living a healthy life. The environment was not polluted and they 
had good physical activity. Their food was free of pesticides. 
 In today’s modern world we follow all hygienic practices right from our 
home. By following all these practices we are able to bring down the 
mortality rate and increase the life expectancy. On the other hand in this 
modern world physical activity is reduced and all edible products we 
consume are treated with pesticides. We also lead a stressful life. All 
these leads to increased morbidity, which is what we pay to this modern 
world for increasing our life expectancy. Both men and women are 
equally affected and some disease are specific for either men or women. 
One among them is Polycystic Ovarian Syndrome (PCOS) which is 
seen exclusively in women of reproductive age group. 
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World Health Organization reports that Polycystic Ovarian Syndrome 
approximately affects 5-10% of the reproductive female population 
worldwide. A study by Ridhi R et al. shows it affects the Indian female 
adolescents approximately by 9.13%
2
. 
 Women with PCOS have chronic inflammation. This in turn leads to 
increased incidence of non-communicable diseases like cardiovascular 
disease and diabetes3. Chronic inflammation in PCOS patients can be 
identified using serum markers such as C - reactive protein [CRP], 
Interleukin-6[IL-6] and Interleukin-18 [IL-18]. 
We did a thorough search of literature in subscribed journals of our 
institute (print and online), PubMed, Ovid, Google, etc., to look for the 
status of inflammatory markers in Polycystic Ovary Syndrome patients. 
Almost all the publications are from the western world (Europe). There 
was only one study from India on the women with Polycystic Ovary 
Syndrome showing the status of Inflammation mainly the atherosclerotic 
markers
3
. All PCOS patients undergo routine investigations like 
Ultrasound abdomen and blood investigations.  
This study was basically carried out to see if there is any association 
between inflammation and PCOS. If the serum inflammatory markers 
are higher, then like western population, there is an association between 
 3 
 
inflammation and PCOS in Indian Population. We would also like to see 
drugs used in PCOS has any influence over the inflammation in PCOS. 
 
 
 
  
 4 
 
AIMS & OBJECTIVES: 
1. To assess the status of inflammation in patients with Polycystic 
Ovary Syndrome (PCOS)  
2. To assess the influence of drugs prescribed for PCOS on 
inflammation 
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REVIEW OF LITERATURE 
PCOS is a disorder with varied presentation which form a wide range of 
signs and symptoms. The presentation may be mild in some and severe 
in others with respect to reproductive, endocrine and metabolic 
functions. The prevalence of polycystic ovaries in general population is 
20-33% detected using ultrasound or other pelvic imaging modalities
 4
.  
The first histological description of polycystic ovary and features of the 
condition was made by Vallisneri in the year 1721. In 1935, it was Stein 
Sr. and Leventhal, two American Gynecologists saw presence of 
ovarian cysts along with anovulation. They described it as Polycysic 
Ovary Syndrome (PCOS). Initially presence of ovarian cysts with 
anovulation was the investigative measures of the disease.Anovulation 
and increased levels of androgens but not the ovarian cysts were made 
the diagnostic criteria later. The histology of polycystic ovary was of an 
ovary with prominent theca, fibrotic thickening of the tunica albuginea 
and multiple cystic follicles
5
. For many years wedge resection was the 
only treatment for PCOS and histological assessment of the ovaries was 
therefore routine practise. The histopathological criteria have been 
defined as the observation of: atretic follicle and/or degenerating 
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granulosa cell, hypertrophy and leutenisation of the inner theca cell 
layer, and thickened ovarian tunica
6
.  
Ultrasound came into the picture during early 1980’s by using high- 
resolution real-time sector scanners7,8. Using ultrasound ovarian 
appearance was described in women classified as having PCOS (by 
symptoms and serum endocrinology). Orsini et al described ovaries as 
either being predominantly solid if fewer than four small (<9mm) cystic 
structures were detected in the ovary or predominantly cystic if multiple 
cystic structures or atleast one large cyst (>10mm) were present
9
. 
Adams et al. defined a polycystic ovary as in one plane, atleast 10 
follicles (usually between 2 and 8mm in diameter) arranged peripherally 
around a thick core of ovarian stroma or dispersed all over in an 
increased amount of stroma according to an abdominal ultrasound
10
. 
When scattered throughout the stroma the cysts were usually between 2-
4mm in diameter
11
. The criteria of Adams and colleagues have been 
implemented by various subsequent reports which used this criteria to 
identify polycystic ovaries
3, 12, 13-18
. Abder Gadir et al found that the 
visualization of the polycystic ovaries supported the diagnosis of the 
syndrome in women with signs and symptoms, rather than being key in 
making the diagnosis
16
. 
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After examining tissues of ovary at hysterectomy or wedge resection it 
was found to have a good correlation between ultrasound diagnosis of 
polycystic morphology and histopathological criteria for polycystic 
ovaries 
19, 20
. 
It was recognized that PCOS is a heterogeneous condition and several 
large series exist that describe populations of patients with the condition. 
The components that define PCOS should include no less than two of 
the following- menstrual disturbance (oligo-anovulation), 
hyperandrogenism and polycystic ovaries. The first largest series of 
polycystic ovaries women was reported by Balen et al who discovered 
this spectrum of the disorder in 1741 patients
21
. 38% of the women were 
overweight. Obesity was related with increased possibility of hirsutism, 
menstrual cycle abnormality and increased rate of infertility. The 
frequency of obesity was reliably large in most of the reports and most 
of them with polycystic ovaries were found to have menstrual cycle 
abnormalities than thin women with polycystic ovaries
21, 22
. Conway et 
al proved mean ovarian volume was higher in polycystic ovaries women 
who are diagnosed through ultrasound than the control group
23
. Franks 
et al established a higher area of uterus and mean ovarian volume was 
doubled in the PCOS group
22
. High serum LH (luteinizing hormone) 
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concentration were linked with infertility or menstrual cycle 
irregularities in both Frank and Balen study. Balen et al also identified 
that elevated levels of serum testosterone were related to increased 
potential of hirsutism, infertility and menstrual abnormalities. Ovarian 
volume strongly associated with serum levels of LH and testosterone 
concentration.   
The incidence of PCOS are highly related to the assessing population’s 
nature. A cross-sectional study by Knochenhauer et al examined the 
prevalence of PCOS in a population of American women to be 4%
24
. 
There is ethnic variation in the prevalence of PCOS. The insulin 
resistance (IR) and symptoms were more in anovular South Asians than 
Caucasians with PCOS
25
. 
In PCOS patients ovary is the primary site of endocrine abnormality 
particularly hyperandrogenism. It was Rosenfield et al who mentioned 
that disorder of P450c17α plays a vital role in overproduction of 
androgen in ovaries
26
. It was later proved by others by injecting one 
dose of gonadotrophin releasing hormone agonist (GnRHa), naferalin to 
hyperandrogenic PCOS women in whom secretion of adrenal androgen 
had been inhibited by giving dexamethasone and their pituitary and 
ovarian response was found
27
. Franks et al extended this study to 
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anovulatory and ovulating hyperandrogenemic women and reported a 
little but substantial rise in androstenedione levels in both groups in 
reaction to GnRHa and an alike response in 17-hydroxyprogesterone 
levels, which were considerably higher in the women with 
anovulation
28
. The elevation of these two hormones was not present 
when ACTH injection was administerd. These results shows that 
hyperandrogenemia in both ovulatory and anovulatory women with 
PCOS is mostly of ovarian origin. 
The distinctive morphology of ovaries is pathognomonic of this disease, 
its chief marker being hyperandrogenemia rising from the theca cells. 
Development of follicles is concerned with antral follicles detained at a 
diameter of 2-9mm. Study of follicle densities showed that normal 
ovaries had 11.4 small preantral follicles/m
3
 (4-34), ovulatory polycystic 
ovaries had a density of 27.4 follicles/m
3
 (9-81), and anovulatory 
polycystic ovaries had a density of 73.0 follicles/m
3
 (31-94). This 
significant difference was also demonstrated for the primary follicles
29
. 
Serum LH concentrations are considerably higher in PCOS women than 
the controls30,31. This is because amplitude and frequency of LH pulses 
are elevated
32
. LH concentrations are increased which are seen in 
approximately 40-60% of PCOS women
32,33,34
. Raised serum LH 
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concentrations has been related todecreased chance of conception and 
high risk of miscarriage
35
. LH levels are predisposed by the temporal 
relation to ovulation, which quickly normalizes LH due to the 
suppressive effect of progesterone. 
The pituitary gonadotropin is foremost to the function of reproduction. 
Its production and secretion of LH and FSH is directly stimulated by 
hypothalamic GnRH and is also affected by integrated feedback 
mechanism. FSH affords the early spur for follicular development and 
also helps alteration of androgens to estrogens in granulosa cells by 
stimulating the aromatase enzymes. LH plays a part in luteal phase by 
stimulating secretion of progesterone, also has a central role in the 
follicular phase, persuading thecal androgen production (substrate for 
estrogen synthesis) and initiating oocyte maturation at mid-cycle. 
A single hypothalamic decapeptide, GnRH stimulates the gonadotroph 
to release both LH and FSH from the gonadotroph36. Pulsatile GnRH 
stimulation is mandatory to maintain gonadotroph secretion. When 
GnRH pulsatility is sluggish FSH secretion outweighs, and when rapid 
LH secretion dominates37. 
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Picture1:Feedback Mechanism of FSH and GnRH on 
Hypothalamus 
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The increasing prevalence of obesity in western society should increase 
our awareness of the possibility of PCOS developing in genetically 
susceptible individuals. The association between obesity and raised free 
androgen levels is strong in women with increased central obesity. 
 
Picture2:Functions of Leptin 
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 Leptin is a 167 aminoacid peptide that is produced by the fat cells in 
reaction to insulin and glucocorticoids. Leptin is conveyed by a protein 
which appears to be the extracellular domain of the leptin receptor 
itself
38
. Leptin declines food intake and induces thermogenesis, it also 
seems to block the hypothalamic neuropeptide-Y, an inhibitor of GnRH 
pulsatility. Leptin appears to aid as the indicator from the body fat to the 
brain about the availability of fat stores for reproduction. Consequently 
menstruation will happen if stores of fat are sufficient. Obesity on the 
other hand is linked with elevated concentrations of leptin and this in 
turn could be a possibility for hyper secretion of LH in women with 
PCOS. 
Many of the symptoms of PCOS are associated with psychological 
disturbance and any symptom may worsen a pre-existing tendency to 
psychological dysfunction. The menstrual cycle is commonly erratic in 
PCOS and periods when they occur are often heavy, prolonged and 
unpredictable. Furthermore in anovulatory women, estradiol acts on the 
endometrium without any opposition since there is absence of 
production of cyclical progesterone. This results in events of uneven 
menstruation, which can lead to endometrial hyperplasia and 
endometrial carcinoma. 
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Menstrual dysfunction brings with it various psychological problems, in 
particular, mood changes, which are often described as being similar to 
premenstrual type symptoms. It is likely that ‘hormonal imbalance’ or 
the erratic nature of the cycle may lead to altered mood and 
psychological distress
41
. 
Insulin resistance and its associated hyperinsulinemia leads to a 
sequence of events collectively called as insulin resistant syndrome. The 
sequence of events include cardiovascular disease, hypertension, 
polycystic ovary syndrome and non-alcoholic steato hepatitis
42
. Insulin 
resistant syndrome and diabetes are inter-related but are different 
entities. All insulin resistant individuals need not be diabetic, but 
develops diabetes only if he is not able to make up the degree of 
hyperinsulinemia needed to overcome the insulin resistance. 
Eventhough an insulin resistant individual need not be diabetic the risk 
of developing the consequences of insulin resistance syndrome are high. 
Patients with insulin resistance syndrome have increased concentrations 
of plasminogen activator inhibitor-1, C-reactive protein and increased 
white cell count. Hence these patients are at increased risk of developing 
PCOS.    
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Picture3:Insulin Resistance and its Complications 
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Picture 4: Insulin Signaling Pathway 
Insulin Receptor 
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Receptor of human insulin is a heterodimer consists of two α, β- 
dimers. A disulfide bond links both these α, β- dimers. The α- subunit is 
extracellular and comprises the binding domain for receptor. The β- 
subunit is intracellular and it contains the intrinsic protein tyrosine 
kinase activity. When a ligand binds to receptor of insulin it causes 
conformational change i.e autophosphorylation of this receptor at 
tyrosine site and promote stimulation of its intrinsic kinase activity. In 
PCOS patients there is fall in insulin receptor autophosphorylation. This 
is because of increased basal autophosphorylation. Phospoaminoacid 
analysis demonstrated insulin-dependent receptor tyrosine 
phosphorylation was reduced and augmented insulin independent 
receptor serine phosporylation
43
. Serine phosphorylation of this receptor 
in initial phases of the insulin signaling pathway causes IR in PCOS 
women. Insulin independent serine phosphorylation of the insulin 
receptor in PCOS women is a sole condition of insulin action as further 
insulin- resistant states like obesity and non- insulin dependent diabetes 
mellitus [NIDDM] do not exhibit this abnormality
43, 44
. 
Low grade inflammation which is of chronic is related to obesity, IR 
syndromes such as polycystic ovary syndrome, and an increased risk of 
cardiovascular disease
45
. In obese patients enlargement of adipose tissue 
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causes adipocyte hypertrophy and hyperplasia and this huge adipocytes 
outshine the local supply of oxygen causing the cell hypoxia 
independently with stimulation of cellular stress pathway
46
. This leads to 
independent inflammation of the cells and cytokines and other pro-
inflammatory signals to get released. As a fragment of this chronic 
inflammatory process, locally released chemokines draws pro-
inflammatory macrophages into the adipose tissue. These then produce 
structures similar to crown round the huge lifeless or dying adipocytes. 
These tissue macrophages release cytokines which then trigger the 
inflammatory process in adjacent adipocytes, aggravating inflammation 
and insulin resistance. There is genetic basis for the inflammation 
observed in PCOS
47
. Variants in genes encoding several pro-
inflammatory cytokines and their receptors associated with insulin 
resistance, obesity and/or diabetes have also been found to be associated 
with PCOS
48-54
. Variants in the gene encoding TNFα
49
, type 2 TNF 
receptor and IL-651-53 and its signal transducer54 have been reported in 
association with PCOS in European population. These findings are in 
conceptual agreement with a common evolutionary background for 
PCOS and metabolic disorders. 
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There is controversy regarding relevance of circulating inflammatory 
molecules because most pro-inflammatory mediators exert their effect in 
tissue in autocrine and paracrine fashion. Interleukin-6 is an endocrine 
cytokine produced by mononuclear cell and adipose tissue that is 
directly responsible for stimulating hepatic CRP synthesis
55-58
. CRP in 
turn has emerged as a major predictor of metabolic dysfunction in 
asymptomatic individuals, and is also produced by adipose tissue
59, 60
. 
Hence C-reactive protein is the most consistent circulating marker of 
low- grade chronic inflammation in PCOS. 
Like C-reactive protein and IL-6, IL-18 is also a proinflammatory 
cytokine which promotes secretion of TNF-α
61
, which furtherstimulates 
the production of IL-6. Interleukin-6 controls the production of CRP in 
the liver. Serum Interleukin-18 levels also correlate with waist-to-hip 
ratio [WHR] and fasting insulin levels. Hence raise in serum IL-18 is 
related to obesity and insulin resistance. Monocyte chemoattractant 
protein-1 [MCP-1] and Macrophage inflammatory protein-1 [MIP-1] are 
other proinflammatory chemokines elevated in polycystic ovary 
syndrome. Monocyte chemoattractant protein plays a major role in the 
development of atherosclerosis, while Macrophage inflammatory 
protein is also called as chemokine [c-c motif] ligand 3 [CCL-3] which 
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shows a significant role in recruitment and activation of leukocytes and 
predicts future cardiovascular events
62
. 
In addition to pro-inflammatory cytokines and chemokines there are also 
other markers of inflammation found to be elevated in women with 
polycystic ovarian syndrome. These include the WBCs, oxidative stress, 
advanced stress, advanced glycation end products, endothelial 
inflammation and infections. 
The WBC[White blood cell] count is found to be elevated in polycystic 
ovarian syndrome women with significant increase in lymphocytes and 
monocytes. Elevation of WBC count in women with polycystic ovarian 
syndrome correlated with the insulin resistance. 
Oxidative stress and inflammation are inter-related. Hence there is an 
association between oxidative stress and diabetes, obesity, metabolic 
syndrome and polycystic ovarian syndrome. Oxidative stress is 
identified by evaluating lipid peroxidation using erythrocyte 
malondialdehyde assay. In patients with polycystic ovarian syndrome 
there is increase in lipid peroxidation and this was directly proportionate 
to body mass index [BMI], insulin levels and blood pressure. In addition 
patients with polycystic ovarian syndrome also have decreased total 
antioxidant status, reduced haptoglobin a protein with antioxidant 
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properties. Hence oxidative stress is directly proportional to insulin 
resistance and reactive oxygen species production by mononuclear cells 
in regard to hyperglycemia which is higher in women with polycystic 
ovarian syndrome. 
When there is a non- enzymatic reaction between reducing sugar and 
amino groups of proteins advanced glycation end products [AGEs] are 
generated. There is induction of oxidative stress when these advanced 
glycation end products act on signal transducing receptors [RAGE]. 
Recent studies demonstrate an elevation of AGE products in women 
with polycystic ovarian syndrome63. 
Chronic low grade inflammation is linked to endothelial inflammation 
and subsequently to endothelial dysfunction. Polycystic ovarian patients 
have endothelial dysfunction this in turn is resistant to insulin induced 
vasodilation. Also polycystic ovary syndrome is linked with various 
markers of dysfunction of endotheliun and inflammation including 
endothelin-1, soluble intercellular adhesion molecule-1 [sICAM-1], 
soluble vascular cell adhesion molecule-1 [sVCAM-1] and plasminogen 
activator inhibitor-1. Hence abnormal endothelial function in polycystic 
ovary syndrome is proportional to its insulin resistance. 
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There are few studies stating that there is an association between 
polycystic ovary syndrome and low grade chronic infections. Patients 
with oligomennorhea and hirsuitism show seropositivity to Chlamydia 
Pneumonia and Chlamydia trachomatis
64
. These patients also have 
elevated high sensitive- C reactive protein. H.Pylori infection was also 
more prevalent in polycystic ovary syndrome women than age matched 
controls
65
. 
The health magnitudes of this syndrome are a lifelong issue. The 
prevalence of impairment of glucose tolerance, insulin resistance and 
diabetes is raised considerably in polycystic ovary syndrome.  
Cardiovascular risk factors comprising high cholesterol levels, 
hyperandrogenemia, hypertension, markers of a prothrombotic state and 
inflammatory markers are increased in women with polycystic ovary 
syndrome. Altered vascular, endothelial function and increased 
incidence of metabolic syndrome are also noted in polycystic ovary 
syndrome. 
Numerous therapies have been projected for the treatment modalities of 
polycystic ovarian syndrome, but the ideal treatment for infertile women 
with polycystic ovarian syndrome has not yet been clear. Drug treatment 
comprises clomiphene citrate, insulin sensitizing agents, gonadotropins 
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and gonadotropin- releasing hormone (GnRH) analogs. Surgical 
treatments include laparoscopic ovarian drilling and the application of 
assisted reproduction techniques. Besides this loss of weight, diet and 
physical exercise have been shown to develop hyper insulinemia, 
menstruation abnormalities and ovulatory rates.  
Polycystic ovary syndrome women develop menstruation irregularities 
owing to abnormal hormonal concentrations which in turn lead to the 
development of endometrial carcinoma, so in a women with menstrual 
irregularities it is more important to prevent development of endometrial 
hyperplasia than to regularize her menstrual cycles. Hence intermittent 
induction of menstruation using progestogens or intake of oral 
contraceptives either cyclically or continuously inhibits atypical 
proliferation of uterus. Combined oral contraceptives is utmost common 
treatment for the symptoms of polycystic ovary syndrome as they 
impede with actions of androgen and reduce androgen production, 
increased hepatic serum hepatocyte binding globulin synthesis, binding 
to androgen receptors competitively by some progestogens. Combined 
oral contraceptives have been revealed to decline insulin sensitivity, 
impair glucose tolerance and alter the lipid profile. Hence use of 
combined oral contraceptives alone for polycystic ovary syndrome make 
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them vulnerable to metabolic distresses. Treatment that combine the 
combined oral contraceptives with insulin sensitizers, antiandrogens, or 
both are developing with possible favorable effects on metabolic 
defects, particularly young females with polycystic ovary syndrome. 
Metformin is a biguanide and is connected to guanidine and galegine. It 
is extracted from the plant Galega officinalis. It was in1922 metformin 
was first defined in works by Werner and Bell as a product in 
production of “N”, “N”- dimethyl guanidine
66
. 
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They found that dicyanodiamide was the precursor to guanidine 
derivatives. Dicyanodiamide when reacts with dimethyl ammonium 
chloride in acidic conditions for three to four hours, then 
dimethyldiguanide [i.e. metformin] is formed in good yields. Interest in 
metformin started in 1950s where metformin did not cause fall in the 
blood pressure and heart rate in animals not like related compounds. 
Garcia thought metformin to have bacteriostatic, antiviral, antimalarial, 
antipyretic and analgesic action. In 1954, Polish Pharmacologist Janusz 
Sipniewski in a series of articles was not able to demonstrate most of 
these effects, including lowered blood sugar
67
. 
Sterne was the first one who used metformin on humans for the 
treatment of diabetes. He published his results in 1957 and called the 
drug “Glucophage” [glucose eater]. Only in 1994 U.S food and drug 
administration [FDA] gave approval for the drug, even though it was 
approved in Canada in 1972
67
. 
Since Polycystic ovary syndrome is linked with insulin resistance, 
antidiabetic therapy has been prepared since late 1980s. It was in the 
University of The Andes where metformin use in polycystic ovary 
syndrome was first started.  In United Kingdom, National Institute of 
Health and Clinical Excellence suggested in 2004 to give metformin for 
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women with polycystic ovary syndrome and body mass index above 25. 
This was prescribed for anovulation and infertility if further treatment 
options failed to yield the results. Metformin is not recommended as the 
first line of treatment for polycystic ovary syndrome by the United 
Kingdom and International Clinical Practice guidelines, except for 
women with glucose intolerance
68
. 
Metformin acts by decreasing hepatic glucose production and increasing 
hepatic glucose uptake. This has been implicated as a major contribution 
to glucose lowering effect. AMP-activated protein kinase (AMPK) 
affords a contender goal mediating useful metabolic possessions of 
metformin. AMPK has a wider part in metabolic processes which 
includes oxidation of fatty acid, glucose uptake by the muscle, glucose 
stimulated genes associated with hepatic lipogenesis. Thus metformin 
by activating AMPK controls type 2 diabetes mellitus
68
. 
Various dose regimens have been projected.  For increasing patient’s 
acceptance metformin is commenced at 500 mg every day as a single 
dose along with food. The dose is raised by 1000 mg after seven days 
and further it is again increased to 1500 mg. The dosage targeted is 
1500–2550 mg/day which is given as 500 or 850 mg thrice daily. The 
effective response is perceived at the dose of 1000 mg once a day. 
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PCOS patients who do not respond to metformin at 1500 mg daily will 
positively respond to 2000 mg daily. Lactic acidosis is one of the 
adverse reaction noted in patients with renal failure, heart failure and 
sepsis.  
Glueck et al showed that metformin has resulted in no main birth 
abnormalities and also no developmental defects in infants at the age of 
3 and 6 months69, 70. One study compared the control group of women 
who was not treated with metformin and the treated group. They showed 
that the prevalence of diabetes during pregnancy in the metformin group 
was considerably less. In new PCOS, metformin compared with placebo 
shows improvement in ovulation rates. Metformin when compared with 
CC showed no advantage in ovulation, pregnancy, or live birth. In new 
PCOS, when metformin or clomiphene is given as single therapy they 
are more effective than the combination of metformin and clomiphene
71
. 
In Clomiphene Citrate resistant patients, it has no advantage in ovulation 
and live birth amounts over placebo as monotherapy. The mixture of 
metformin and Clomiphene citrate enriched ovulation and pregnancy 
than CC alone
72, 73
. Pre-treatment with Metformin increases the 
effectiveness of this drug in PCOS patients
74
. 
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Beyond its effect on glucose metabolism metformin also plays a role in 
reduction of plasminogen activator inhibitor (PAI)-1, von Willebrand 
factor (vWF), smooth muscle cell (SMC) contractility via agonist 
induced increase in intracellular (Ca
2+
) or a secondary increase in nitric 
oxide
75
. 
Metformin also plays a role in inflammation by decreasing 
inflammatory markers in plasma including soluble intercellular adhesion 
molecule, vascular cell adhesion molecule-1, macrophage migration 
inhibitory factor and C-reactive protein (CRP) in case of Polycystic 
ovary syndrome. IL-8 plays a dominant part in recruitment of 
monocytes and adhesion to endothelial cells in atherosclerosis and IL-6 
plays a role in acute phase response. Metformin hinders IL-1β 
stimulated IL-6 and IL-8 manifestation exhibiting the mechanism 
through which metformin therapy attenuates inflammation. In smooth 
muscle cells of human in atherosclerotic plaques there is stimulation of 
multipotent pro-inflammatory transcription regulator. Metformin acts by 
inhibiting NF-κB activation hence modulates inflammatory response to 
IL-1β
76
. 
EL Mekkawi SF, ELHosseiny AS, et al. showed that there was a 
decrease in interleukin-6 and interleukin-18 level after metformin 
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treatment for three months in polycystic ovary syndrome patients. This 
shows metformin decreases the inflammatory markers and have 
beneficial effect on inflammatory process of PCOS
77
.    
Troglitazone is also an insulin-sensitizing drug which improves the 
ovulation and the pregnancy. But, because of its liver toxicity, it has 
been taken away from the market.  Alternative medication in the 
similargroup, rosiglitazone (8 mg/day) which shows to augment 
impulsive and also clomiphene-stimulated ovulation in PCOS women
78
. 
Pioglitazone also seems to be in effect. But its safety is also questioned. 
Foetal safety has not been recognised for both rosiglitazone and 
pioglitazone which comes under pregnancy category C of US FDA 2 
guidelines.  
Tang et al recently reviewed the insulin-sensitizing drugs like 
metformin, rosiglitazone, pioglitazone, and d-chiro-inositol for PCOS 
females, oligo/amenorrhea, and subfertility. They finalised that 
metformin is beneficial in the pregnancy and also ovulation. Though, 
there is no proof that metformin rises birth rates when this is given as 
monotherapy or combined with clomiphene. Thus, the usage of 
metformin in improving fertility consequences in women with PCOS 
seems to be limited
79
. 
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Even small amounts of FSH administered into the circulation along with 
FSH injections or with pulsatile GnRH or clomiphene citrate, is adept of 
stimulating ovulation and pregnancy in a huge number of women with 
PCOS with anovulation. It has been in effect in ovulation induction for 
PCOS women and considered to be the main line treatment of those 
patients. Clomiphene citrate is a partial oestrogen agonist. Clomiphene 
citrate is strictly related to the oestrogen chlorotrianisene. Absorption of 
this compound through oral route is efficient. Its half-life is 5–7 days 
and is excreted through urine mainly. It has strong binding to protein 
and enterohepatic circulation and is circulated to adipose tissues.  
The estrogenic agonistic actions are well seen in animals with gonadal 
deficiency. It blocks the oestrogenic actions. It causes an increase in the 
production of gonadotropins and oestrogens by blocking the negative 
feedback effect of estradiol on the gonadotropins. The importance of 
this drug is seen on its efficiency to induce ovulation in oligomenorrhea 
or amenorrhea women and disorder of ovulation. Clomiphene blocks the 
feedback inhibitory stimulus of oestrogens on the hypothalamus, leading 
to a rush of gonadotropins, which causes ovulation. 
Generally, one ovulation is stimulated by a single course of drug, and 
the patient must be treated subsequently till the pregnancy is reached, as 
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normal ovulatory action does not usually occur. The drug has no role in 
ovarian or pituitary failure patients. When clomiphene is given in a dose 
of 100 mg/d for 5 days, an increase in plasma LH and FSH is seen after 
many days. In ovulatory patients, there is an early rise followed by 
another rise of gonadotropin levels just preceding to ovulation. Careful 
monitoring of ovarian response with serial ultrasound scans is essential 
and in those who respond sensitively to 50mg, a lower dose of 25 mg 
may be used. A duration of three to six ovulatory cycles is usually 
adequate to distinguish whether pregnancy will be attained using 
clomiphene citrate, before going on to a multifaceted treatment, as 
around 75% of the pregnancies attained with clomiphene citrate happen 
in the first three cycles of treatment
80
. If the patient is ovulating, it is not 
essential to raise the dose even if conception has not resumed, and 
conception is anticipated to happen at a rate determined by influences 
like the patient’s age. All women who are given with clomiphene should 
be cautiously observed with combined endocrine and ultra-sonography 
assessment of follicular growth and ovulation, for the reason of multiple 
pregnancy
81
. 
 Ovulation occur in about 80% but then end result of pregnancy is only 
approximately 35-40% of patients who are given clomiphene
82
. 
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Clomiphene citrate normalises LH and increase FSH secretion. This 
result in inducing follicle growth and ovulation. Various studies reported 
clomiphene to be the standard treatment for the patients of polycystic 
ovary syndrome for their induction of ovulation
83, 84
. A meta-analysis 
showed use of clomiphene citrate in PCOS women compared to placebo 
has six times more potency to result in pregnancy
83
. In practice, the 
usual regimen is an initial dose of 100 mg once a day from day 4 or 5 
and this has no benefit by a daily dose of more than 150 mg which 
appears to considerably increase either the ovulation rate or follicular 
recruitment. This type of schedule will decrease the number of 
‘superfluous’ cycles of therapy until those resistant to clomiphene are 
identified. 
A prospective study on the follow-up of lean women with disorder of 
ovulation has reported more conception rates in patients responding to 
ovulation who are being treated with clomiphene. 50% achieved 
ovulation after three cycles and 75% after nine cycles of treatment
83
. 
Despite its efficacy some women do not ovulate and do not achieve 
pregnancy due to its adverse effects on endometrium like 
hyperandrogenemia, ovarian volume, menstrual irregularities and 
obesity. Also patients with increase basal LH have less chance to 
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respond to clomiphene
85
. Kousta et al showed treatment with 
clomiphene citrate for 167 patients showed a rate of 67.3% of 
conception over six months in patients who do not have any subfertility 
factors
86
. These patients were continued with twelve cycles of therapy. 
They described a multiple pregnancy rate of 11%, like to that referred in 
other series, and a miscarriage rate of 23.6%, with those who had 
miscarriage because of high LH levels immediately after clomiphene 
administration. 
Shoham and colleagues observed the hormonal profiles in forty one 
women cured with clomiphene citrate of whom twenty eight ovulated87. 
In those who ovulated, 17 had normal patterns of hormone secretion and 
five of them conceived. 11 of them who showed abnormal patterns of 
hormonal profile, high levels of LH from day 9 until LH spur, along 
with premature luteinisation and high concentrations of estradiol 
throughout the cycle, did not conceive. 
If pregnancy was not achieved even after 10-12 normal ovulatory cycles 
it is then apt to suggest the couple assisted conception. The addition of 
an ovulatory dose of human chorionic gonadotropin (hCG), 5000-10000 
IU can be administered if the cause for non-ovulatory response is 
delayed LH surge or absent of it even in the occurrence of a well-
 34 
 
developed follicle. The repetitive administration of hCG at mid-cycle 
result in little enhancement of conception rates if given when follicle 
reaches a diameter of 18-24 mm. 
Daily doses of dexamethasone, 0.5 mg at bedtime, as an aide to 
clomiphene citrate treatment, suppress the production of adrenal 
androgen and may stimulate receptiveness to clomiphene in former non-
responders, commonly PCOS hyper androgenic women with increased 
levels of dehydroepiandrosterone sulphate (DHEAS)
 88, 89
. But side 
effects are more with this method.                      
A systematic review by Misso M et al. shows that combination of 
Clomiphene Citrate and metformin are improved than placebo for 
increasing ovulation and pregnancy rates. But CC is superior to 
metformin for ovulation, pregnancy and live-birth rates, in PCOS 
patients with body mass index (BMI) >30. A combined CC and 
metformin is more efficacious than metformin alone or CC alone, 
depending on the BMI and CC sensitivity of the patient
90
.  
A Prospective trial was conducted to compare the ovulation and 
pregnancy rates in infertile CC alone and combined metformin and CC 
PCOS women for three cycles of escalating the dosage from 50 mg till 
150 mg alone compared with CC and then another 150 mg for three 
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cycles. Another group were given the same amount of CC along with 
1500mg of metformin. Up to six cycles ovulation or pregnancy was 
assessed by transvaginal sonography. Rate of ovulation and pregnancy 
in combination with metformin and CC was greater than CC alone. 
Moreover, the study showed metformin augmented the ovulatory rate in 
CC failures indicating increased responsiveness to CC
91
.  
Clomiphene citrate does not show any effect on inflammation in PCOS. 
Menstrual irregularities are the most common symptom that occur in 
polycystic ovary syndrome. Amenorrhoea or oligomennorrhea is the 
primary complaint. In normal menstrual cycle oestrogen will be 
produced during ovulation and progesterone will also be secreted. The 
shedding of endometrium occurs if pregnancy doesn’t occur. This is 
Secretory phase.  
For this phase progesterone is necessary. In PCOS progesterone are not 
secreted and hence there will be no shedding of endometrium. If this is 
continued the lining of cells which are not shredded gets accumulated 
and can lead to endometrial hyperplasia. So regular shedding is 
necessary. This can occur by giving low dose of progestogens cyclically 
and this induces regular menstruation. It can be given every month 
during secretory phase alone in low dose. Progestin after entering into 
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the cell gets bind to progesterone receptors which are dispersed in the 
middle of the nucleus and the cytoplasm. The ligand-receptor complex 
gets fixed to a progesterone response element (PRE) to stimulate the 
transcription of gene. The specificity of reaction is available in the cell 
and also other cell-particular receptor co regulators and relating 
transcription factors. The progesterone-receptor complex forms a dimer 
formerly tying to DNA. Like the oestrogen receptor, it can form 
heterodimers and in addition to homo dimers between two isoforms, A 
and B. These isoforms are delivered by optional splicing of the same 
gene
92
.  
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Progesterone has little impact on protein metabolism. It empowers 
lipoprotein lipase action and appears to favour fat deposition. The 
consequences on carbohydrate metabolism are more distinct. 
Progesterone increments basal insulin levels and the insulin reaction to 
glucose. There is normally no difference in carbohydrate tolerance
92
.  
Receptor of the renal tubule, bringing about a reduction in Na
+
 
reabsorption. This prompts to a high production of aldosterone by the 
adrenal cortex (eg, in pregnancy). Progesterone rises body temperature 
in humans. The mechanism of this process is not known, but a change in 
the hypothalamus on the temperature-regulating centers has been 
recommended. Progesterone also changes the function of the respiratory 
centers. The ventilatory response to CO2 is raised by progesterone but 
synthetic progestins with an ethinyl group don’t have respiratory causes. 
This causes to an amountable decrease in arterial and alveolar PCO2in 
the pregnancy and in the luteal phase of the menstrual cycle. In the 
brain, progesterone have depressant and hypnotic effects too.  
In breast, it is the reason for the development of the alveolobular 
secretory components. It also involves the preovulatory LH spur and 
leads to the maturation and secretory alterations in the endometrium 
which occur after ovulation. 
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 Regular treatment with progestin can cause breast engorgement, rise in 
body temperature, headache, depression, weight gain, irregular 
menstrual cycle, breakthrough bleeding. Severe cases can lead to 
amenorrhoea. 
The frequency of menstrual cycles is less significant than the occurrence 
of endometrial hyperplasia. Intermittent induction of menstruation 
utmost usually by progestogens or oral contraceptives, either cyclically 
or continuously, inhibits abnormal uterine proliferation. Use of 
combined oral contraceptives (COCs) is the usual treatment for the 
symptoms of polycystic ovary syndrome. The COCs help to prevent 
recurrent anovulatory bleeding by providing a progestin and by 
suppressing ovarian hormones and adrenal androgen production. They 
also, indirectly, increase sex hormone–binding globulin (SHBG). SHBG 
binds to androgens and reduces their circulating concentrations. 
Combined oral contraceptives decreases insulin sensitivity, impairs 
glucose tolerance, and alters lipid profiles in healthy women, but 
apparently it do not affect the risk of diabetes mellitus or cardiovascular 
disease
92
. 
Combined oral contraceptive pills contain low dose oestrogens and 
progestin so that side effects are minimised. If the patient contain 
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hirsutism and acne more estrogenic preparation can be preferred. There 
are monophasic, biphasic and triphasic combination pills
92
. 
Monophasic pills contain no phasic increase or decrease in the oestrogen 
/progestin content during 21 days of pill administration. The first pill is 
taken on the fifth day after the start of the menses. Thereafter, one pill is 
to be taken each day consecutively for 21 days. Then, next seven days 
are “pill free period” and the next course starts again after the fifth day 
of menses. On repeating this schedule, the cycle becomes anovulatory 
(due to estrogenic effect) with a regular cyclic menstrual bleeding on 
withdrawal of the pill (due to progestogenic effect). Biphasic and 
triphasic pills mimic the hormonal changes during the menstrual cycle 
as physiologically as possible. Biphasic pills have a fixed dose of 
oestrogen for twenty one days but with increasing doses of progesterone 
during two successive phases i.e. from the day one to ten and eleven to 
twenty one. Next seven days are pill free days. Triphasic pills provide a 
bit higher dose of oestrogen at near mid cycle but increasing doses of 
progesterone for three successive phases i.e. for days one to six, seven to 
eleven and twelve to twenty one days. 
The combination pills supress the ovulation by inhibiting the release of 
FSH and LH [mainly estrogenic effect]. High doses of oestrogen also 
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inhibit LH surge. The role of progesterone is to ensure withdrawal 
bleeding after stopping the medication. Normal ovulatory cycle is 
regained within one to three months of stopping the COC
92
. 
COCs can also be combined with Cyproterone acetate (CPA) which is 
an anti-androgen. This not only regulates menstrual cycle but also 
effective in reducing the symptoms of hyperandrogenism such as 
hirsutism and acne. This in turn prevents endometrial hyperplasia. 
Cyproterone acetate (CPA) act chiefly by meddling with target tissue 
binding of androgens to their intracellular receptor. They are used as 
monotherapy or as combined therapy with COCs for masculinizing 
signs that are not reactive to a single drug. Anti-androgens will improve 
sensitivity to insulin slightly in PCOS women
93
. They competitively 
blocks receptors of androgen intracellularly, but it has less activity than 
spironolactone. The fall in LH-dependent androgen synthesis is ascribed 
to the progestational activity of CPA and ethinyl estradiol (EE) that is 
given with it to deliver contraception and also blocks LH. Upto 50-90% 
patients a clinical effect in hirsutism if CPA has been taken regularly for 
2-3 months. 35µg of EE and 2 mg of CPA is mostly combined. As 
PCOS is a progressive syndrome, at least up to the age of forty, it is 
necessary to treat the patient with EE and CPA. This combination can 
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reduce androgen levels distinctly and also their adverse reactions. It will 
make the disease ‘on hold’. So that the fertility rate increases even when 
the drug is discontinued. Other contraceptive drugs given periodically 
will regularize the periods and should be substituted after six months 
with the higher dose EE/CPA combination-since there is a chance of 
high possibility of thromboembolism. Cyclical progesterone therapy 
(using the less androgenic progestin such as medroxyprogesterone 
acetate and dehydrogesterone) may also be used to induce regular 
menstruation. A progesterone releasing IUCD may also be used to 
provide endometrial protection
93
.       
Falsetti L and Passinetti E studied the effects of combination of 0.035 
mg of ethinylestradiol and 2 mg of cyproterone acetate on lipid 
metabolism in women with polycystic ovary syndrome (PCOS). For 
this, 72 PCOS women were given with thirty six repetitive cycles of EE 
and CPA. Profiles of hormones, lipid and sugar were read before and 
after 12 and 36 cycles of treatment. The treatment repressed 
gonadotropin and androgen levels and improved the concentrations of 
sex hormone binding globulin. After 12 and 36 cycles a substantial raise 
in triglycerides, high density lipoprotein (HDL) cholesterol system, and 
apoprotein B levels were perceived. Insulin and plasma glucose levels 
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had no change. During management triglycerides, total cholesterol and 
apoprotein B levels were more than the control group. There were no 
change in concentrations of LDL-C and HDL-C in PCOS and in the 
control group. Lipid and lipoprotein alterations seen after treatment can 
be because of oestrogen dominance of the treatment
94
.  
Maturation of oocytes is the final process of an immature female egg 
cells before fertilisation either in normal or stimulated ovarian cycles. 
Gonadotropins are the next line treatment for fertility in anovulatory 
women with PCOS
95
. Follicle Stimulating Hormone (FSH) stimulates 
growth of follicles, ova development and production of oestrogens. 
Luteinizing Hormone (LH) stimulates preovulatory expansion of the 
ripe Graafian follicle and induces ovulation and then leutinization of the 
ruptured follicle and corpus luteum is sustained till the next menstrual 
cycle. Progesterone secretion occurs only under the influence of LH. 
GnRH action gonadotropins occurs via a G-protein coupled receptor 
which exerts its action by stimulating intracellular Ca2+ through 
hydrolysis of phophotidyl inositol phosphate
96
. The production of 
gonadotropins raises at puberty and is more in women compared to men. 
In the follicular phase, moderate levels of FSH and low levels of LH 
will be present. There is a mid-cycle spur of both, but more of LH, just 
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before ovulation, followed by subsequent decrease in the luteal phase. 
Inadequate gonadotropins secretion results in amenorrhoea and sterility 
in women. However excess production of gonadotropins in women 
causes polycystic ovaries
97
. The gonadotropins causes induction of 
ovulation, maintenance and incite ideal growth of follicle through a 
regulated injection of FSH, and attain a follicular size which is able to 
get fertilize. Gn doesn’t put forth an antiestrogenic action peripherally. 
The major disadvantage of Gn is the formation of many follicles so that 
increases the ovarian hyper stimulation syndrome (OHSS) and multiple 
pregnancies. FSH injection requires skill and rigorous monitoring and 
also very expensive and needs more time
98
. Various therapy designs are 
employed like step-up, low-dose step-up, and step-down regimens. The 
ASRM vouch for low-dose gonadotropin protocols99.  The step-up 
regimen starts with dosage from 37.5–50 IU/day which is minimum and 
this is being increased regarding the deficiency of follicular response. 
The response are monitored using ultrasound and then treatment is 
altered 1 week later if there is no follicular development with an 
increase of 50% every time as needed.  
HCG is useful as a substitute in the LH spur which causes maturation of 
the oocyte, follicular rupture and corpus luteal production. The step-
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down course commences with the extreme suggested dose, which is then 
decreased as a follicle response is attained. The dose is reduced 50% 
every time when the therapy is altered. Current reports described higher 
protection for patients using the step-up regimen
100
. 
In 2006, the ASRM implied severe control when blood estradiol 
concentrations crossed 2500 pictogram/mL at the time of 
induction99. Recent suggestions advise withholding hCG injection in the 
availability of greater than two follicles >16 millimetre or greater than 
one follicle >16 millimetre and two extra follicles >14 millimetre, or if 
serum estradiol concentrations are within 1000 and 2500 pictogram/mL, 
especially in female less than 38 years old who had no other infertility 
causes. So low-dose regimens ended in a monofollicular ovulation rate 
of ∼70%, a pregnancy rate of 20% each cycle, and multiple live birth  of 
5.7% even then the incidence of multiple pregnancies was around <6% 
and OHSS was around<1%
101
. A maximum of six cycles with 
gonadotropins is suggested since no action even for six cycles suggest 
their presence of resistance. 
It is mainly attempted to stimulate ovulation along clomiphene citrate 
when failed or during anovulation which can be because of polycystic 
ovaries. 
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The usually used dosage of hCG in IVF is 10,000 International Units but 
studies shows 5,000 International Units is sufficient to yield similar 
results
102
. These hormones act on women for their fertility and ovulation 
and not on inflammation. 
In 1850 Johannes Joseph Scherer
103
was the first man to isolate 
hexahydroxycyclohexane from muscle and named it Inositol as it 
belongs to the sugar family104. The hexahydroxycyclohexane structure 
has 9 different stereo isomers. Among them, Myo-inositol is the most 
distributed isomer in the body. It has both metabolic and functional 
importance. Myo-inositol is thought to be a prebiotic molecule105 and 
inositol and inositol-derivatives has various roles in biological systems. 
Later inositol was found to be the main component of phytates which is 
the salts of inositol hexaphosphoric acid. In 1914, Anderson
106
showed 
the molecular structure of myo-inositol- 1, 2, 3, 4, 5, 6-hexakis 
dihydrogen phosphate which is said also as phytic acid and confirmed 
by various modern analytical methods
107
. 
Inositol is found in foods like fruits and beans
108
. Myo-inositol is 
incorporated into the cell wall as phosphatidyl myo-inositol, the pioneer 
of inositol triphosphate which acts as a second messenger regulating the 
mechanism of hormones such as FSH, TSH and insulin. Addition to it, 
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inositol is an important component of the structural lipids
109
. After 
Scherer, many researchers started to study the role of inositol in 
different organs and tissues specifically its role in cell shape and oocyte 
fertility. In 1964, Eisenberg et al
110
, and Eisenberg and Bolden
111
 found 
that testes are rich of free inositol; later, Voglmayr and Amann
112
, Lewin 
and Beer
113
, and Ghafoorunissa
114
 reported that the prostate, the 
epididymis and seminal vesicles contain a large amount of myo-inositol. 
The seminal fluid is one of the richest sources of inositol. The 
concentration of inositol in seminal fluid is almost three times higher 
than that found in plasma
115, 116
.  
These primary findings gave the first indirect proof relating inositol 
based molecules to germ-cell (spermatozoa and oocytes) physiology.  In 
1974, Larner reported the presence of various intracellular chemical 
mediators of insulin, and hypothesized that, after the binding of insulin 
to its receptor; different intracellular pathways could be triggered 
according to the specific mediator involved
117
. In 1988 Larner et al
118
 
was drawn to a conclusion that the two inositol stereo isomers, Myo-
inositol and D-chiro-inositol, are present. They are the chemical 
mediators of insulin. These both act through different mechanisms but 
have same forms, changing only in the stereochemistry of having one 
hydroxyl group
119
.  
Natural sources for these inositols are endogenous biosynthesis and 
dietary intake. Myo
two steps. First, glucose
phosphate, which is dephosphorylated by an inositol monophosphatase 
enzyme giving free myo
 
 
 
 
Picture 5: Formation of Myo
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-inositol is produced from glucose-6-phosphate in 
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-inositol
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In vivo, D-chiro-inositol is synthesized by an epimerase that converts 
myo-inositol into D-chiro-inositol.  
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Picture 6: Conversion of Myo-inositol to D-chiro-inositol 
 
 
 
 
 
 
 
 
 
Larner first studied a decreased D-chiro-inositol content in urine as well 
as tissues of human subjects and animals with type 2 diabetes
119, 121
. He 
postulated that the myo-inositol when converted to D-chiro-inositol 
requires stimulation of insulin
122
. This conversion is decreased in the 
insulin sensitive tissues like fat, liver, muscles of rats
123
. 
PCOS pathogenesis is linked to insulin resistance and/or compensatory 
hyperinsulinemia irrespective of their BMI whether they are lean or 
obese. The impairment in the insulin signaling in PCOS could be due to 
 
Myo-inositol 
 
D-chiro-inositol 
Epimerization 
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a defect in the inositol phosphoglycans (IPGs) second messenger 
pathway
119
opened a new angle in the clinical management of PCOS. 
IPGs have a role in stimulating enzymes that regulate glucose 
metabolism
124, 125
. In PCOS women, a defect in tissue availability or 
altered metabolism of inositol or IPGs mediators may contribute to 
insulin resistance
126
. In 1999, Nestler JE et al. published Ovulatory and 
metabolic actions of D-chiro-inositol in the polycystic ovary syndrome 
assessed steroids level in serum and oral glucose tolerance tests before 
and after the oral administration of 1200 mg of D-chiro-inositol or 
placebo for six to eight weeks in 44 obese PCOS patients once daily. 
The results proved that PCOS patients who received D-chiro-inositol 
has improved insulin sensitivity and serum free testosterone levels were 
reduced than the placebo group. In addition to it, diastolic and systolic 
blood pressure, and plasma triglyceride levels were decreased in patients 
treated with D-chiro-inositol. Ovulation occurred in 19 out of 22 women 
(86%) who received D-chiro-inositol , as compared to 6 out of 22 (27%) 
in the placebo group
127
.  
In 2002, Nestler and Allan reported a clinical study in which they saw 
whether administration of D-chiro-inositol would affect the levels of 
circulating insulin and androgens, and the occurrence of ovulation in 
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lean PCOS patients. These  results confirmed earlier findings which 
showed in lean PCOS women also, D-chiro-inositol reduces serum 
insulin and androgen and also improves  PCOS-associated metabolic 
abnormalities (increased blood pressure and hypertriglyceridemia)
128
. 
Chiu et al in 1992 published a study which showed an increased 
concentration of inositol in patients with successful IVF pregnancies. 
This indicates the involvement of inositol in the early phase of in vitro 
IVF and also for the maintenance of normal development of embryo. 
They also reported that patients who had successful IVF pregnancies 
and also those who had high levels of myo-inositol showed the 
development of the embryos with higher number of somities
129
. Same 
group of authors
130
 after ten years conducted a study to examine whether 
the content of myo-inositol in human follicular fluid was associated with 
good oocyte quality. For this fifty three patients who had been treated 
with IVF were recruited and their follicular fluid and serum were 
collected. Then they have been divided into two groups with group A 
consisting follicular fluid with matured and fertilized oocytes and group 
B has immature follicles and unfertilized oocytes. There was a statistical 
significance of correlation between the levels of myo-inositol in the 
follicular fluid and the quality of oocytes. This showed greater follicular 
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concentration of myo-inositol is associated with greater follicular 
maturity. So concentration of myo-inositol is a quality marker for 
evaluation for oocytes. 
Unfer et al. conducted a study on myo-inositol administration in PCOS 
patients. Twenty five patients participated in this study and they were 
given myo-inositol and folic acid twice daily. Their ovulatory activity 
was seen through sonography and hormonal profile, number of 
spontaneous menstrual cycles and pregnancies were noted. The results 
obtained showed the efficacy of myo-inositol in simultaneous ovarian 
activity and fertility in PCOS patients131. 
Following this study many authors
132, 133
reported daily intake of myo-
inositol improves hormonal profile, restores ovulation, and induces 
regular menses in PCOS patients who are both lean and obese. 
Rizzo et al. reported the efficacy of myo-inositol and folic acid in 
fertility improvement in PCOS patients compared to Myo-inositol plus 
folic acid and melatonin. Unfer et al. again showed there was no 
difference in myo-inositol and D-chiro-inositol treated groups on the 
number of oocytes but mature oocyte number was increased and the 
immature oocytes got decreased in myo-inositol group
134
. 
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In patients with PCOS there was a myo-inositol depletion which 
resulted in poor oocytes
135
. This myo-inositol depletion result in 
impairment of FSH signaling in PCOS patients
136
. Various studies 
reported shows the need of rFSH got decreased during IVF cycles when 
myo-inositol supplemented three months before the stimulation of 
ovary
134, 135,137
. 
Isabella and Raffone140 showed increase in D-chiro-inositol will produce 
ovary toxicity which is characterized by poor quality of oocyte and 
reduced response of ovary to FSH. Another study by Galetta M et al. 
showed healthy volunteers had high myo-inositol concentration and low 
D-chiro-inositol concentration. But PCOS patients had opposite ratio. 
This is called “DCI paradox”
141
. 
Nowadays combined treatment of D-chiro-inositol and myo-inositol are 
also being given. Minnozi et al. showed the combined therapy of myo-
inositol and D-chiro-inositol was able to improve the metabolic 
consequences of PCOS women, thus decreasing the cardiovascular risk 
factors. In this study twenty obese PCOS patients were taken and their 
lipid profile such as HDL, LDL, Triglycerides were assessed before and 
after six months of treatment with combination therapy. Changes in 
body mass index, waist-hip ratio, body fat percentage, blood pressure 
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and HOMA-IR were evaluated. There was a strong increase in HDL 
levels and decrease in LDL and Triglycerides levels. Reduction in 
HOMA-IR was also seen concluding that the combination therapy 
improves the metabolic profile
142
.   
N-acetyl cysteine(NAC) acts by inhibiting the stress of oxidation and 
preventing the increased glucose levels which stimulates the resistance 
of insulin. A study by Fulghesu et al.143 illustrated the patients with 
PCOS who had increased insulin levels when treated with N-acetyl 
cysteine, treatment with NAC resulted in progress of insulin sensitivity 
in addition to marked decrease in concentrations of testosterone and 
lipids. Kilic-Okman and Kucuk
144
has showed NAC decreases serum 
testosterone and insulin levels and improved homocysteine in addition 
to lipids in PCOS patients. Study by Rizk et al
145
. reported the 
combination of CC and NAC rises the rates of both ovulation and 
pregnancy in infertile CC-resistant patients infertile. N-acetyl cysteine 
plus clomiphene citrate when compared with clomiphene citrate alone 
showed improved follicular growth. Thus emphasizing that N-acetyl 
cysteine is effective in inducing and maturing the oocytes. A study by 
Saghar Salehpour et al
146
. reported that N-acetyl cysteine induces 
enhancement in profile of lipids, hormones, rate of ovulation, and as a 
 55 
 
result the health outcomes of PCOS women. This is via the block stress 
of oxidation in addition to increasing the sensitivity of insulin in the 
tissues peripherally. The adverse drug events were very less due to NAC 
and hence it is taken into consideration for treatment of PCOS women. 
As described earlier it is not only the anovulation but also decrease in 
the quality of oocyte and embryo were the reason for infertility in PCOS 
women. Poor oocyte quality is due to ROS-induced oxidative stress. 
Raise in lipid peroxidation products in serum as well as in follicular 
fluids were studied by various authors 
147,148
. Sun C.L.et al showed 
apoptotic granulosa cells is more in PCOS females149.  
  
 Picture 7: Mechanism of action of Melatonin
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The major enzymatic metabolite of melatonin 6-sulfatoxymelatonin 
levels in urine is more in PCOS women than the female without 
PCOS
150
. LH production, and LH reaction to GnRH were enhanced due 
to elevated melatonin levels
150
. This high levels of melatonin may be 
due to feedback action to the lack of melatonin in the ovary. With this 
current understanding of actions melatonin may be a potential treatment 
for PCOS in the future. 
Statins are the blocks of 3-hydroxy-3-methyl-glutaryl-coenzyme A 
(HMG-CoA) reductase. It is the rate limiting process in the synthesis of 
cholesterol pathway. They strongly inhibit the secretion of cholesterol 
which is a substrate for testosterone as well as improves 
hyperandrogenemia. Apart from this they limit the mechanisms of 
insulin and IGF-1 on the ovary. This is done with the help of reducing 
N-linked glycosylation so that there will be maturation of insulin and 
Type 1 IGF-1 receptors. Not only this they also reduce isoprenylation of 
small GTPases such as Ras and Rac which are the mediators of insulin 
signaling pathway
151
.  
 
Statins blocks the mevalonate pathway which lead to abolition of the 
actions of increase of insulin levels on the proliferation and 
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steroidogenesis of thecal cells. They also inhibit the oxidative stress 
which causes increase in proliferation of cells, steroidogenesis and 
insulin resistance. So these two roles result statins to have a better effect 
in the PCOS and its effect on the cardiovascular mortality and 
morbidity.   
Laparoscopic ovarian drilling is the surgical method in women with 
clomiphene-resistant PCOS and who persistently hyper secrete LH. 
After the surgery actions of ovary is restored and concentrations of LH 
and testosterone level fall
152
. Hence surgery helps to bring down the 
levels of LH and androgen even in patients with elevated LH 
concentrations. So laparoscopic ovarian drilling is more effective in 
patients with menstrual irregularities and increases the fertility rate in 
women who come to infertility clinics 
153
.  
Even though these many drugs and modalities of treatment were 
available for PCOS, only few drugs targeted in reduction of 
inflammation. There were various studies, as we quoted earlier, 
demonstrating the effect of inflammation on PCOS. These studies were 
all done in other parts of the world. There were very less number of 
studies done in India. So we proposed to study the status of 
inflammation on PCOS in Indian population in particular South Indian 
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population. There were also as we said earlier studies on drugs targeting 
on inflammation in PCOS. These studies mainly spoke about metformin 
and their anti-inflammatory properties. There were no studies 
demonstrating the anti-inflammatory effect of other drugs used to treat 
PCOS in practise.  
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MATERIALS AND METHODS 
This study was a prospective cross sectional study. The study 
population was from all the patients who attended the outpatient 
Department of Obstetrics and Gynecology in PSGIMSR Hospital, 
Coimbatore. We included all the PCOS patients according to Rotterdam 
consensus criteria with age group 18-45 years and excluded those 
patients presenting with a history of inflammatory diseases or intake of 
inflammatory drugs and also pregnant women. Healthy Volunteers of 
age group 18- 45 years women with normal reproductive cycle were 
included and those who present with history of inflammatory drugs or 
diseases are excluded. Further those who have hypertension or diabetes 
are also excluded from the healthy volunteers. 
The overview of the study design is given in the figure below. The 
patients were divided into three groups. 
Group 1: Healthy volunteers  
Group 2:  Newly diagnosed PCOS 
Group 3:  Already on treatment for PCOS 
Sample size estimated according to previous literature search.30 
participants in each group was taken. 
Healthy female 
volunteers
30 
volunteers
Blood tests
• hsCRP
• IL-6
• IL-18
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Newly diagnosed 
PCOS
30 patients
Blood tests
• hsCRP
• IL-6
• IL-18
Already on 
treatment for 
 
 
 
PCOS
30 patients
Blood tests
• hsCRP
• IL-6
• IL-18
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The study design was submitted to the Institute Human Ethics 
Committee (IHEC) stating its purpose preceding the study. The details 
and the usefulness of the study design were described to every 
participant individually and clarified their doubts before getting the 
informed consent forms. The informed consents forms provided to the 
participants were either in English or in Tamil. The participants, who 
gave written informed consent, came under the inclusion criteria were 
enrolled for the study. Healthy volunteers were also given the informed 
consent. The copy of consent forms were attached in the annexure. The 
patients who declined to give informed consent were also excluded from 
the study. 
PCOS patients were selected according to Rotterdam Consensus Criteria 
2003 which is given below. 
• Polycystic ovaries(12 or more follicles in each ovary, each 
follicle measuring 2-9 mm in diameter and/or ovarian volume > 
10 ml, one polycystic ovary is sufficient for diagnosis) 
• Oligo-/anovulation; clinical diagnosed as Oligo-/amenorrhea 
(menstrual cycles longer than 35 days or less than 10 
menstruation/year) 
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• Hyperandrogenism (clinical or biochemical) 
Basic demographic data like name, age and anthropometric 
measurements of Height, weight, body mass index were recorded. 
History of the patient, any co morbidities was noted. If the patient is on 
already treated group then their treatment history were noted. 
Our study was to observe if there were abnormalities in High sensitivity 
C - reactive protein, Interleukin-6 and Interleukin-18 in PCOS patients 
and to compare those with the healthy volunteers. 
Sample for High sensitivity C - reactive protein (hs-CRP) was collected 
in red topped vacutainer which is a tube without any anticoagulant. 
The blood samples for Interleukin -6 (IL-6) and Interleukin -18 (IL-18) 
were collected in yellow topped vacutainer which had acid citrate 
dextrose as anticoagulant. 
The high sensitivity CRP was tested in the Clinical Biochemistry lab 
using the Cobas Integra C - reactive protein (Latex). This machine 
works by the methodology of “Particle enhanced turbidimetric 
assay”. When Human CRP is applied over the monoclonal anti-CRP 
antibodies, it agglutinates due to exposure of latex particles. The 
precipitate is determined turbidimetrically at 552nm.Sample collected 
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was centrifuged and the serum was used for analyses. The analyzer 
automatically calculates the analyte concentration of each sample. The 
value <0.05mg/dl was considered to be normal. 
The Interleukin-6 was estimated in the Pharmacology laboratory using 
Krishgen Biosystems, imported from California, USA. The IL-6 
enzyme immunoassays are programmed for measuring the quantity of 
human interleukin-6(IL-6). Samples and other requirements used for 
quantification are coated in microtiter plate which are previously coated 
with first monoclonal Ab, anti IL-6 in the presence of second Ab linked 
to streptavidin Horseradish peroxidase (streptavidin-HRP). Later when 
the incubation period is over these wells are washed and with the help of 
a colored substrate the enzymatic activity is detected. This color is 
proportional to the Interleukin-6 concentration in the serum sample.  
Serum was obtained by allowing the blood to clot for 30 minutes and by 
centrifuging it for 10 minutes at 1000 x g. Then they were stored. Then 
the serum was separated carefully from clot in a separate plastic tubes 
and stored at <-20 degree C. 
The kit contains a plate with ready to use 96 wells. The reagents were 
prepared for assaying IL-6. 5 ml of 20X wash buffer was added to 95 
ml and 1 ml of 5X Assay diluents to 4 ml of distilled water. 25 
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microliters of Detection Ab to 9975 microliters of 1X Assay Diluents 
to get a final volume to 10 ml and 50 microliters of streptavidin-HRP 
to 9950 microliters of 1X Assay Diluents to get final volume to 10 ml 
were added. Recombinant protein was diluted by adding 20 microliters 
of std. solution in 10 ml of 1X Assay Diluents and top standard solution 
2000pg/ml was prepared. Six two-fold serial dilutions were prepared 
from the top standard solution 2000picogram/ml such that 
concentrations are 1000picogram/ml, 500picogram/ml, 250picogram/ml, 
125picogram/ml, 62.5picogram/ml, 31.3picogram/ml and 1X assay 
diluents serve as zero standard. 
 
100µl/well of standards and samples were added to the plate. After 
sealing it was incubated at 37 degree C for 1 hour and 30 minutes.The 
wells were washed at least for 4 times using the wash buffer 1X and the 
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plate was turned upside-down and tapped firmly onto a clean absorbent 
paper.100µl of diluted Detection Ab was added to all wells and the plate 
was kept for incubation at 37 degree c for 90 minutes. Again the wells 
were washed using wash buffer 1X and 100 microliters of diluted 
streptavidin-HRP was added to each well after which the plate was 
sealed and incubated at 37 degree c for 30 mins. Wells were washed for 
four times following which it was soaked in wash solution for 30 to 60 
seconds in between every wash to minimize the background error. 
Finally, freshly prepared TMB substrate 100 microliters was added to 
each well and was kept in the dark for 15 to 30 minutes. The wells 
showing positive reaction turned blue in color after which the reaction 
was stopped by adding 100 microliters of stop solution. 
The plate was then inserted into an ELISA reader and the absorbance 
read at 450 nm within 30 minutes of adding stop solution. ELISA reader 
is a Bio-Rad system which is attached to a computer which has curve 
fitting software. The unknown concentrations of interleukin-6 were then 
identified by plotting the graph. 
The Interleukin-18 was assessed in the Pharmacology laboratory using 
Krishgen Biosystems,imported from California, USA. This ELISA kit 
is based on the principle of double-antibody sandwich ELISA technique 
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to detect Interleukin 18 (IL-18) in body fluids. The kit uses a double-
antibody sandwich enzyme-linked immuno-sorbent assay (ELISA) to 
determine the amount of Human Interleukin 18 (IL-18) in a biological 
sample. Samples are added to micro-plate wells pre-coated with Human 
Interleukin 18 (IL-18) antibody. After incubation and washing, Human 
Interleukin 18 (IL-18) detection antibodies labeled with biotin is added.   
After incubation and washing Streptavidin-HRP is added to form 
immune complex, followed by incubation and washing to remove the 
uncomplexed enzymes. Then chromogenic TMB substrate solution is 
added, the color of the liquid changes to blue. Stop HRP enzyme 
reaction by addition of acid stop solution, when color changes to yellow. 
The intensity of color developed is proportional to the concentration of 
the Human Interleukin 18 (IL-18) present in the sample and read at 
450nm using a plate reader. 
Serum was obtained by allowing the blood to clot for 30 minutes and by 
centrifuging it for 10 minutes at 1000 x g. Then they were stored. Then 
the serum was separated carefully from clot in a separate plastic tubes 
and stored at <-20 degree C. 
The kit contains a plate with ready to use 96 wells. The reagents were 
prepared for assaying IL-6. 5 ml of 20X wash buffer was added to 95 
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ml and 1 ml of 5X Assay diluents to 4 ml of distilled water. 25 
microliters of Detection Ab to 4975 microliters of 1X Assay Diluents 
to get a final volume to 10 ml and 50 microliters of streptavidin-HRP 
to 9950microliters of 1X Assay Diluents to get final volume to 10 ml 
were added. Recombinant protein was diluted by adding 20 microliters 
of std. solution in 10 ml of 1X Assay Diluents and top standard solution 
2000pg/ml was prepared. 
 Six two-fold serial dilutions were prepared from the top standard 
solution 2000picogram/ml such that concentrations are 
1000picogram/ml, 500picogram/ml, 250picogram/ml, 125picogram/ml, 
62.5picogram/ml, 31.3picogram/ml and 1X assay diluents serve as zero 
standard. 
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100µl/well of standards and samples were added to the plate. After 
sealing it was incubated at room temperature for 90 minutes.The wells 
were washed at least for 4 times using the wash buffer 1X and the plate 
was turned upside-down and tapped firmly onto a clean absorbent 
paper.100µl of diluted Detection Ab was added to all wells and the plate 
was kept for incubation at room temperature for 90 minutes. Again the 
wells were washed using wash buffer 1X and 50 microliters of diluted 
streptavidin-HRP was added to each well after which the plate was 
sealed and incubated at room temperature for 30 mins. Wells were 
washed for four times following which it was soaked in wash solution 
for 30 to 60 seconds in between every wash to minimize the background 
error. Finally, freshly prepared TMB substrate 100 microliters was 
added to each well and was kept in the dark for 15minutes. The wells 
showing positive reaction turned blue in color after which the reaction 
was stopped by adding 100 microliters of stop solution. 
The plate was then inserted into an ELISA reader and the absorbance 
read at 450 nm within 30 minutes of adding stop solution. ELISA reader 
is a Bio-Rad system which is attached to a computer which has curve 
fitting software. The unknown concentrations of interleukin-6 were then 
identified by plotting the graph. 
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Statistical Analysis: 
Statistical analysis were performed by using SPSS software version 19. 
The results were analyzed using one way ANOVA and post hoc 
analysis was done using LSD. 
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RESULTS 
We included the patients who attended Obstetrics and Gynecology 
department and diagnosed to have PCOS. Their history when asked was 
more likely of amenorrhea or infertility. Of these, regarding infertility 
patients when history was asked it was found those patients have history 
of oligo/amenorrhea. Other patients were excluded. 
The statistical analysis done was One-way ANOVA and post hoc LSD 
using SPSS software version 19. 
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Figure 1 shows the age distribution of the study population 
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There were no patients above 40 years of age. 73.3% of newly 
diagnosed patients and 66.67% of already diagnosed patients are in the 
3
rd
 decade. 
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Figure 3 represents the history of the patients
 The patients attended the outpatient department either for menstrual 
abnormality or infertility treatment. 
 
66.67% of newly diagnosed and 60% of already diagnosed patients h
attended outpatient department for menstrual abnormality either for 
oligomenorrhea or amenorrhea. Rest of the patients came for infertility 
treatment. 
0
5
10
15
20
25
Menstrual abnormalities
 
 
 
Infertility
HISTORY
 
 
 
82 
 
ave 
GROUP II
GROUP III
Figure 4 represents the marital
 
 
60% of the newly diagnosed patien
patients were unmarried.40% of the newly diagnosed patients and 20% 
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Figure 5 represents the newly diagnosed study population with 
thyroid disease 
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Figure 6 represents the already diagnose
thyroid 
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Figure 7 represents the newly diagnosed study p
prolactin levels 
 
 
50% of the newly diagnosed study population had normal prolactin 
levels.  
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Figure 8 represents the already diagnosed PCOS study p
with Prolactin levels
 
 
36% of the study population had normal prolactin levels.
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Figure 9 represents the therapies in the already diagnosed group
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Table 1 represents the percentage of drug treatment in the same 
group 
Drug Percentage 
Metformin Combination 70 
Myoinositol Combination 33.33 
Hormones 23.33 
Clomiphene citrate 20 
Human Chorionic Gonodotropin injection 13.33 
Laproscopic Ovarian Drilling 3.3 
 
70% of the study population in already diagnosed group were on 
Metformin combination and 33.33% of the study population were in 
Myoinositol Combination. 
  
  
 
Figure 10 represents the combination of drugs
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Myo – Myo-inositol
Clomi – Clomiphene citrate
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Drugs Percentage 
Only Metformin 46.67 
Metformin + Myoinositol 13.33 
Myoinositol + Clomiphene citrate  10 
Metformin+ Clomiphene citrate 6.67 
Myoinositol + HCG + Clomiphene citrate 6.67 
Myoinositol + Metformin + Clomiphene citrate 6.67 
Myoinositol + HCG 3.33 
Metformin + HCG 3.33 
Myoinositol + HCG + LOD 3.33 
 
46.67% of patients were prescribed with Metformin alone and 
metformin along with myoinositol were prescribed for 13.33% of 
patients. Myoinositol with Clomiphene citrate were given for 10% of 
patients and Metformin and Clomiphene citrate were given for 6.67% of 
patients. 
  
  
 
Figure 11 represents the duration of treatme
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Table 3 and Table 4 represents the comparison of hs-CRP for the 
three groups.  
Table 3: One way ANOVA: 
 F p-value 
Between groups 
Within Groups 
0.025 0.975 
 
Table 4: Post Hoc (LSD) analysis: 
Between Groups 
Comparison 
Mean Difference p-value 
I and II 0.00667 0.963 
I and III 0.02433 0.867 
II and III 0.03100 0.831 
 
There was no difference between the newly diagnosed and already 
diagnosed study population and there was no statistically significant 
decrease in the hs-CRP level in between the groups. 
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Table 4 and Table 5 represents the IL-6 level. There was no difference 
between the newly diagnosed and already diagnosed study population 
and there was no statistically significant decrease in the IL-6 level. 
 
Table 4: One-way ANOVA: 
 F  p-value 
Between groups 
Within groups 
0.293 0.746 
 
Table 5: Post hoc (LSD) analysis: 
Between Groups 
Comparison 
Mean Difference P-value 
I and II 56.23703 0.746 
I and III 57.06563 0.506 
II and III 0.82860 0.992 
 
 
  
  
 
Figure 13 represents the 
 
 
0
10
20
30
40
50
60
70
80
90
100
LE
V
E
LS
IL-6 levels between three groups
 
I II
GROUPS
INTERLEUKIN-6
96 
 
 
III
  
 
97 
Table 6 and Table 7 represents the IL-18 levels. We were not able to 
establish a impact between the two population.  
 
Table 6: One way ANOVA: 
 F p-value 
Between groups 
Within Groups 
1.954 0.148 
 
 
Table 7: Post hoc (LSD) analysis: 
Between Groups 
Comparison 
Mean Difference P-value 
I and II 133.417 0.114 
I and III 150.75323 0.074 
II and III 17.33650 0.836 
 
 
  
  
 
Figure 14 shows the 
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Figure 15 represents the hs
treatment. When mean values were compared between the patients 
whose duration of treatment was less than six months and more than six 
months the values has reduced but it was not statistically significant 
(p=0.188). 
 
 
< 6 MONTHS
0.5147
-CRP levels with regard to the duration of 
 
> 6 MONTHS
0.2536
hs-CRP
< 6 MONTHS > 6 MONTHS
99 
 
  
 
Figure 16 represents the IL
treatment. There was no statistical significance (p=0.230) between the 
patients with less than six mont
six months of treatment but their mean values have reduced.
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Figure 17 represents the IL
treatment. There was a reduction in the mean values between the less 
than six months and more than six months treatment but there was no 
statistical significance between them (p=0.441).
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Figure 18 represents the IL-6 levels
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DISCUSSION   
This study was intended to evaluate the status of inflammation, by 
measuring hs-CRP, IL-6 and IL-18, in PCOS patients in Indian 
population. It was also aimed to assess the influence of drugs prescribed 
in PCOS patients on the inflammation. 
Polycystic Ovary Syndrome is an endocrine disorder which is very 
common in the female population in the reproductive age group
24
. Most 
women shows the features of metabolic syndrome. It is also concomitant 
with hypertension, diabetes, dyslipidaemia, gestational type 2 
diabetes
154
. 
PCOS is associated with obesity and also increased incidence of insulin 
resistance155. There is also increased risk of cardiovascular 
complications. The inflammation which is of chronic low grade is 
related to PCOS. The C-reactive protein levels is an acute phase reactant 
and is circulating marker of cardiovascular events. CRP > 3mg/L in a 
patient is equal for metabolic syndrome as in ATP III guidelines. IL-6, 
TNF-α, IL-18 concentrations in serum are the predictors of 
cardiovascular events
3
. Hence, in this study we proposed to measure the 
IL-6, IL-18 and hs-CRP levels in PCOS patients in Indian population. 
There are various studies showing the significance of IL-6, IL-18 and 
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hs-CRP in PCOS in other countries. There are no studies showing this 
significance in Indian Population. 
There were many therapies of polycystic ovarian syndrome include 
clomiphene citrate, insulin sensitizing agents, gonadotropins and 
gonadotropin- releasing hormone (GnRH) analogs, laparoscopic ovarian 
drilling and the application of assisted reproduction techniques. Apart 
from this weight loss, diet and exercise have been shown to improve 
hyperinsulinemia, menstrual abnormalities and ovulation rates
156
. In 
previous studies drugs like metformin and thioazolidinones like 
pioglitazone, rosiglitazone decreases insulin resistance and also known 
to decrease the inflammation. Other drugs like myo-inositol, clomiphene 
citrate improves ovulation alone. Their role in inflammation was not 
known in PCOS. 
Ninety participants were recruited in this study. These participants were 
divided into three groups as normal controls, newly diagnosed patients 
and already diagnosed on treatment patients. The age group in normal 
controls was 40% in 3
rd
 decade and 60% in 4
th
 decade. The age group in 
newly diagnosed was 73.3% and already diagnosed was 66.67% in the 
3
rd
 decade whereas in 4
th
 decade it was 13.33% and 26.67% 
respectively. In normal controls there were no patients in <20 years of 
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age whereas in newly diagnosed and already diagnosed on treatment 
groups 13.33% and 6.67% were under 20 years of age respectively and 
no patients in the age of more than 40 in all the three groups (Figure 1).  
On comparing patients’ weight, there were 53.33% in normal controls, 
43.33% in newly diagnosed and 50% in already on treatment groups 
have Normal weight. Overweight was 30%, 36.67%, 33.33% in Normal 
controls, newly diagnosed, already on treatment groups respectively. 
13.33%, 3.33%, 13.33% participants were obese in normal controls, 
newly diagnosed, already on treatment groups. Only 3.33% were 
underweight in both normal and already diagnosed on treatment group 
participants whereas in newly diagnosed there were 16.67% (Figure 2). 
In newly diagnosed and already diagnosed on treatment group, 
participants attended outpatient department of Obstetrics and 
Gynaecology for both menstrual abnormalities either amenorrhoea or 
oligomenorrhoea and Infertility. Out of thirty participants in newly 
diagnosed PCOS, 66.67% and 33.33% attended the outpatient for 
menstrual abnormalities and for infertility. In already diagnosed patients 
60% and 40% attended due to menstrual abnormalities and infertility. 
Thus participants in both the groups attended the outpatient department 
mostly for oligo/amenorrhoea (Figure 3). In newly diagnosed patients 
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60% of the patients were married and in already diagnosed patients 80% 
of the patients were married. In married patients most of the patients 
came with the history of infertility (Figure 4). 
Only 6.67% in newly diagnosed and 6.67% in already diagnosed 
patients were hypothyroid and they were on treatment on levothyroxine. 
Seven patients (23.33%) in newly diagnosed and six patients (20%) in 
already diagnosed patients’ level of thyroid was not found. Remaining 
patients were normal in both the groups (70% and 73%) (Fig.5 &6). 
In case of prolactin levels, in newly diagnosed fifteen patients (50%) 
have normal levels and for another fifteen patients (50%) levels were 
not found. In already diagnosed on treatment group it was normal for 
eleven patients (36%) and abnormal for 2 patients (6.67%). It was not 
checked for seventeen patients (56.6%) (Fig.7&8). 
Low grade chronic inflammation is associated with Polycystic Ovary 
Syndrome and it can be assessed using inflammatory markers like IL-6, 
IL-18 and hs-CRP. These are strong predictors of cardiovascular 
complications. An article proposed by Samy et al compared PCOS 
patients with BMI matched controls and reported that there is a 
significant increase in hs-CRP, IL-6 and TNF-α only in the obese group 
of patients. They have also showed a positive correlation between these 
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inflammatory markers and HOMA index which was used to measure the 
insulin resistance
157
. Kelly et al. reported a study exhibiting an increase 
in CRP which shows a low grade chronic inflammation in PCOS 
patients. In this study they showed mean value of PCOS patients was 
greater than normal controls
3
. 
Here in this study there was no significant increase in the CRP levels 
(p=0.975). There was no significant difference between the newly 
diagnosed and already diagnosed patients suggesting that hs-CRP didn’t 
rise significantly in already diagnosed group as they were on treatment 
(Table 3 & 4) (Figure 13). 
In the same way there was also no significant changes in the IL-6 levels 
(p=0.746). There was an increase in their mean values when compared 
to normal controls. Mean value for normal controls was 34.35+93.88 
whereas for newly diagnosed patients it was 90.58+308.62 and for 
already diagnosed it was 91.41+476.6 suggesting there was a rise in IL-
6 levels in PCOS when compared to normal controls but that was not 
significant. Between newly diagnosed patients and already diagnosed 
patients there was no much difference between the levels (Table 5 &6) 
(Figure 14).   
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Another study by Hector et al showed there was an increase in IL-18 
independent of obesity
158
. Here in this study the results showed there 
was an increase in the mean values of IL-18 in PCOS patients when 
compared to normal controls. The mean value for Normal control was 
131.4+224.17 whereas for newly diagnosed and already diagnosed 
group of patients it was 264.86+316.33 and 282.2+403.92 respectively. 
The difference was not statistically significant (p=0.148) (Table 7&8) 
(Figure 14). There was also, as in IL-6, no difference in newly 
diagnosed and already diagnosed patients.   
When we considered the treatment prescribed to the patients in already 
diagnosed group, most of the patients were in Metformin combination 
(Table 1). Nearly 70% of patients were in metformin combination 
(Figure 9). Metformin was given along with myoinositol, clomiphene 
citrate, Human Chorionic Gonadotropins (HCG). Only 46.67% patients 
were on monotherapy of metformin (Table 2).  
 
The other common drug prescribed was myoinositol combination. It was 
around 33.33% patients who were prescribed with this combination. It 
was also given along with metformin, clomiphene citrate and HCG. 
Metformin along with myoinositol was given to 13.3% of patients. 
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Menstrual abnormality was one of the chief complaints of the patient 
(60%) in this group. So they were given low dose of medroxy 
progesterone, ethinylestradiol, Cyproterone acetate for about seven 
patients (23.3%). As patients come for infertility (40%) they were given 
clomiphene citrate (20%) and HCG (13.3%) injection. Laparoscopic 
Ovarian Drilling was done for one patient out of the thirty patient and 
she was prescribed with myoinositol and HCG injection later.  
 86.67% of patients were on these treatment for less than 1 year and only 
13.33% of patients were on these therapies for more than 1 year (Figure 
11).  
Mekkawi et al stated that there was a statistical significant change in the 
Interleukin-6 and Interleukin-18 levels before and after metformin 
therapy showing metformin decreases the inflammatory markers in 
PCOS patients
77
. In previous studies it was known that there was an 
increase in the Nuclear Factor κ B (NFκB) in PCOS. Metformin inhibits 
NFκB which inhibits IL-1β and inhibits the production of pro 
inflammatory gene
75
. 
 In this study, the mean + SD for hs-CRP, IL-6,IL-18 were decreased 
between the patients who were on treatment for less than six months and 
more than six months (Figure 15,16,17). But there was no statistical 
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significance in the hs-CRP (p=0.188), IL-6 (p=0.230) and IL-18 
(p=0.441) between these two group of patients. We could also see a 
decrease in the mean values of hs-CRP, IL-6 and IL-18 as there was an 
increase in the duration of treatment (Figure 18, 19, 20). 
Our results were consistent with Mohlig et al. who showed there was no 
substantial decrease in CRP and IL-6 levels. In their study these levels 
were increased in both normal and PCOS obese patients compared to the 
lean patients. There was a positive relationship between the obesity, 
insulin resistance and inflammatory markers than the PCOS itself. When 
a linear regression was done in their study it showed obesity was the one 
which increases the inflammatory marker than the insulin resistance
52
. 
Another study by Escobar-Morreale et al. also showed obesity causes an 
increase in the inflammatory marker and not the disease itself
159
.  
In this study we had only 13.3% of obese study population in the 
already diagnosed and on treatment group and 3.33% in the newly 
diagnosed PCOS group. Also in this study there were about 86.7% of 
already diagnosed group of patients’ on treatment for less than one year. 
So even though there was a fall in the mean values of inflammatory 
markers there was no statistical significance in them. 
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The lack of statistical significance may be due to small sample size in 
each group and wide range of values between the patients. The duration 
of treatment which was less than one year in most of the patients and 
hence the effect of drugs on the inflammatory markers could not be 
assessed. As this was a cross sectional study and blood samples were 
taken at one time the difference in the inflammatory markers could not 
be studied for the same group of patients. The influence of drugs 
prescribed were also in combination for most of the patients and so they 
could not be studied individually. 
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SUMMARY & CONCLUSIONS: 
Though there are various pharmacological drugs available to treat 
PCOS, only few drugs targeted in reduction of inflammation. There 
were various studies, as we quoted earlier, demonstrating the effect of 
inflammation on PCOS. These studies were all done in other parts of the 
world. There were very less number of studies done in India. So we 
proposed to study the status of inflammation on PCOS in Indian 
population in particular South Indian population.  
The pro inflammatory cytokines were produced when NFκB was 
stimulated. Metformin inhibits this NFκB and thus reduces the 
inflammation. Other drugs used in PCOS in practise like myoinositol, 
clomiphene citrate, hormones target at the disease per se and not on the 
inflammation produced by the disease. 
This study has shown that mean values of inflammatory markers were 
increased in Polycystic Ovary Syndrome (PCOS) in newly diagnosed 
and already on treatment for PCOS. 86.7% of the patients who were on 
already treatment for PCOS group were on treatment for less than one 
year. It has shown that there was an inversely proportional relationship 
between the mean values of inflammatory markers and duration of 
treatment.  
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We suggest larger follow up studies with longer duration of treatment so 
that influence of drugs on the inflammatory markers can be studied 
exhaustively in Indian population. Further studies are needed to 
demonstrate the effects of drugs for PCOS targeting on the 
inflammatory pathway so that these drugs not only brings down the 
severity of PCOS but also reduces the cardiovascular risk factors 
associated with it.    
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ABBREVIATIONS 
Ab – Antibody 
AMPK  – Adenosine Monophosphate Kinase 
AGE  – Advanced Glycated End products 
ASRM  – American Society of Reproductive Medicine 
CC  – Clomiphene Citrate 
CRP  –  C - reactive protein 
FSH  –  Follicle Stimulating Hormone 
GnRH  – Gonadotropin Releasing Hormone 
GnRHa  –  Gonadotropin Releasing Hormone agonist 
hs-CRP – High sensitivity C- reactive protein 
HRP  – Horse Radish peroxidase 
IL-6  – Interleukin-6 
IL-18  – Interleukin-18 
IL-8 – Interleukin-8 
IL-1β – Interleukin-1β 
IR  – Insulin Resistance 
IVF  – In Vitro Fertilization 
LH – Luteinizing Hormone 
NAC  – N-Acetyl Cysteine 
NFκB – Nuclear Factor kappa B 
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PCOS  – Polycystic Ovary Syndrome 
ROS  – Reactive Oxygen Species 
Std.  – Standard 
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                                      CASE REPORT FORM  
NAME :  
AGE : 
O.P. NUMBER : 
HEIGHT : 
WEIGHT: 
HISTORY: 
 
DRUG HISTORY: 
 
USG FINDINGS: 
 
INTERLEUKIN-6: 
INTERLEUKIN-18: 
hs CRP: 
FSH :LH (if done) : 
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PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
I,Senthurselvi R.  am carrying out a study on the topic: A CROSS SECTIONAL STUDY ON THE 
STATUS OF INFLAMMATORY MARKERS IN POLYCYSTIC OVARY SYNDROME(PCOS) 
PATIENTS IN INDIAN POPULATION  as part of my research project being carried out under the 
aegis of the Department of PHARMACOLOGY.  
 
My research guide is: Dr.K.BHUVANESWARI,Professor and Head of the 
department,Pharmacology. 
 
The justification for this study is: PCOS is prevalent nowadays. There are no studies 
demonstrating the role of inflammation in patients with PCOS in Indian population and also how 
the drugs prescribed for PCOS influences the inflammation. 
 
 
The objectives of this study are:  
 
Primary Objective: To assess the status of inflammation in patients with PCOS 
 
Secondary Objective: to assess the influence of drugs prescribed for PCOS on inflammation 
 
 
Sample size:90..  
 
Study volunteers / participants are (specify population group & age group): Patients diagnosed 
to have PCOS and also healthy volunteers with age group between18-45 years. 
 
Location:the study will be conducted in PSGIMS&R hospital.  
 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration):20 minutes.  
 
Data collected will be stored for a period of five years. We will not use the data as part of another 
study. 
 
Health education sessions: Number of sessions:one. Approximate duration of each session:  
 
20 minutes.  
 
Clinical examination (Specify details and purpose): Height and Weight for BMI 
 
Blood sample collection: Specify quantity of blood being drawn: 5 ml.  
 
No. of times it will be collected: 1 
 
Whether blood sample collection is part of routine procedure or for research (study) purpose:   
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 Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: pain while pricking 
 
Whether blood sample collected will be stored after study period: No, it will be destroyed 
 
Whether blood sample collected will be sold: No  
 
Whether blood sample collected will be shared with persons from another institution: No 
 
Medication given, if any, duration, side effects, purpose, benefits: No 
 
Benefits from this study: PCOS is prevalent nowadays. There are no studies demonstrating the 
role of inflammation in patients with PCOS in Indian population and also how the drugs prescribed 
for PCOS influences the inflammation. 
 
Risks involved by participating in this study: No risks 
 
How the results will be used: Clinical meeting at PSG Hospitals 
                                                Dr.MGR Medical University dissertation 
 
If you are uncomfortable in answering any of our questions during the course of the interview / 
biological sample collection, you have the right to withdraw from the interview / study at 
anytime. You have the freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you so decide, will not result 
in any form of compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a patient. You will 
NOT be paid any remuneration for the time you spend with us for this interview / study. The 
information provided by you will be kept in strict confidence. Under no circumstances shall we 
reveal the identity of the respondent or their families to anyone. The information that we collect 
shall be used for approved research purposes only.You will be informed about any significant new 
findings - including adverse events, if any, – whether directly related to you or to other participants 
of this study, developed during the course of this research which may relate to your willingness to 
continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has 
been explained to me by the investigator/s. Having understood the same, I hereby give my 
consent to them to interview me. I am affixing my signature / left thumb impression to indicate my 
consent and willingness to participate in this study (i.e., willingly abide by the project 
requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
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PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
I,Senthurselvi R.  am carrying out a study on the topic: A CROSS SECTIONAL STUDY ON THE 
STATUS OF INFLAMMATORY MARKERS IN POLYCYSTIC OVARY SYNDROME(PCOS) 
PATIENTS IN INDIAN POPULATION  as part of my research project being carried out under the 
aegis of the Department of PHARMACOLOGY.  
 
My research guide is: Dr.K.BHUVANESWARI,Professor and Head of the 
department,Pharmacology. 
 
The justification for this study is: PCOS is prevalent nowadays. There are no studies 
demonstrating the role of inflammation in patients with PCOS in Indian population and also how 
the drugs prescribed for PCOS influences the inflammation. 
 
 
The objectives of this study are:  
 
Primary Objective: To assess the status of inflammation in patients with PCOS 
 
Secondary Objective: to assess the influence of drugs prescribed for PCOS on inflammation 
 
 
Sample size:90..  
  
Study volunteers / participants are (specify population group & age group): Patients diagnosed 
to have PCOS and also healthy volunteers with age group between18-45 years. 
 
Location:the study will be conducted in PSGIMS&R hospital.  
 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration):20 minutes.  
 
Data collected will be stored for a period of five years. We will not use the data as part of another 
study. 
 
Health education sessions: Number of sessions:one. Approximate duration of each session:  
 
20 minutes.  
 
Clinical examination (Specify details and purpose): Height and Weight for BMI 
 
Blood sample collection: Specify quantity of blood being drawn: 5 ml.  
 
No. of times it will be collected: 1 
 
Whether blood sample collection is part of routine procedure or for research (study) purpose:   
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 Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: pain while pricking 
 
Whether blood sample collected will be stored after study period: No, it will be destroyed 
 
Whether blood sample collected will be sold: No  
 
Whether blood sample collected will be shared with persons from another institution: No 
 
Medication given, if any, duration, side effects, purpose, benefits: No 
 
Benefits from this study: PCOS is prevalent nowadays. There are no studies demonstrating the 
role of inflammation in patients with PCOS in Indian population and also how the drugs prescribed 
for PCOS influences the inflammation. 
 
Risks involved by participating in this study: No risks 
 
How the results will be used: Clinical meeting at PSG Hospitals 
                                                Dr.MGR Medical University dissertation 
 
If you are uncomfortable in answering any of our questions during the course of the interview / 
biological sample collection, you have the right to withdraw from the interview / study at 
anytime. You have the freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you so decide, will not result 
in any form of compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a patient. You will 
NOT be paid any remuneration for the time you spend with us for this interview / study. The 
information provided by you will be kept in strict confidence. Under no circumstances shall we 
reveal the identity of the respondent or their families to anyone. The information that we collect 
shall be used for approved research purposes only. You will be participating in this study as a 
healthy volunteer to assess the normal limits. You will be informed about any significant new 
findings - including adverse events, if any, – whether directly related to you or to other participants 
of this study, developed during the course of this research which may relate to your willingness to 
continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has 
been explained to me by the investigator/s. Having understood the same, I hereby give my 
consent to them to interview me. I am affixing my signature / left thumb impression to indicate my 
consent and willingness to participate in this study (i.e., willingly abide by the project 
requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
